Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Hunan Province Tumor Hospital
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- BECOME
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 12000
- sponsor
- Hunan Province Tumor Hospital
- conditions
- Lung Cancer
- interventions
- DRUG: Pemetrexed plus Pembrolizumab; DRUG: Pembrolizumab; DRUG: Pemetrexed
- start date
- 2021-10-01
- start date type
- ACTUAL
- primary completion date
- 2025-07-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05055908
- Published
- Sep 24, 2021
- Updated
- Aug 2, 2024
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05055908
- Categories
- Lung Cancer
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials